The challenge to patent law of pure chemical protein synthesis.
作者信息
Fellmeth Aaron Xavier
机构信息
Arizona State University College of Law, P.O. Box 877906, Tempe, Arizona 85287-7906, USA.
出版信息
Nat Biotechnol. 2005 May;23(5):547-9. doi: 10.1038/nbt0505-547.
PMID:15877067
Abstract
摘要
相似文献
1
The challenge to patent law of pure chemical protein synthesis.
Nat Biotechnol. 2005 May;23(5):547-9. doi: 10.1038/nbt0505-547.
2
Reach-through claims for drug target patents: Rx for pharmaceutical policy.
Nat Biotechnol. 2008 Jan;26(1):55-6. doi: 10.1038/nbt0108-55.
3
Patent watch.
Nat Rev Drug Discov. 2008 Nov;7(11):882-3. doi: 10.1038/nrd2751.
4
Old drugs, new uses: solving a Hatch-Waxman patent predicament.
Food Drug Law J. 2004;59(1):155-68.
5
Should the patent system for new medicines be abolished?
Clin Pharmacol Ther. 2007 Nov;82(5):488-90. doi: 10.1038/sj.clpt.6100393.
6
US policy may encourage counterfeit drugs.
Nat Biotechnol. 2003 Feb;21(2):121. doi: 10.1038/nbt0203-119.
7
Navigating the Hatch-Waxman Act's safe harbor.
Food Drug Law J. 2002;57(3):475-89.
8
Overview of the Hatch-Waxman Act and its impact on the drug development process.
Food Drug Law J. 1999;54(2):187-94.
9
ACOG Committee Opinion. Number 364 May 2007. Patents, medicine, and the interests of patients.
Obstet Gynecol. 2007 May;109(5):1249-54. doi: 10.1097/01.AOG.0000263899.30167.eb.
10
The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
J Contemp Health Law Policy. 1992 Spring;8:361-78.
Zotero 插件